DNTH
Dianthus TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Primary sources show multiple shots on goal around claseprubart: early CAPTIVATE GO language in CIDP, a planned gMG Phase 3 start in mid-2026, and MMN data in 2H 2026, while March 2026 FDA feedback reduced a visible screening/safety-framing overhang across trials [#10-K-2026-03-09] [#8-K-2026-03-26].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +13.3.
What can break
Clinical readouts remain binary and can overwhelm favorable operational updates.
Momentum
82
Value
41
Sentiment
27
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $82.00 · Bull $115.00 · Bear $55.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $128.69
Why
Momentum82 · Δ7d +13.3
Value41 · Δ7d +0.0
Sentiment27 · Δ7d -8.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
82
26% active weight
Current posture
7d trendImproving
Δ7d
+13.3
Δ21d
-5.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
27
34% active weight
Current posture
7d trendSoftening
Δ7d
-8.9
Δ21d
-9.7
Why this grade
Composite grade D. Momentum 82.2 / Value 41.1 / Sentiment 26.7
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$5.77B
Beta
1.59
Shares Out
54.67M
P/E (TTM) · Derived
-25.1
P/S (TTM)
513.87
P/FCF (TTM) · Derived
-33.79
Rev YoY
-60.2%
EPS YoY
+3.1%
Gross Margin
+72.2%
Op Margin
-4558.4%
Net Debt
-$402.91M
Current Ratio
29.25
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology